The outlook of companies tied to flagship drugs like Viagra presents a complex investment picture. While the initial rise of copyright, fueled by Viagra's extraordinary popularity, generated substantial returns, the expiry in key territories has introduced substantial risk . Investors are now facing the effect of rival medications , shrinking sales